Observational studyRheumatology international2020

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.

Jesús Loarce-Martos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.